<code id='9C3CCB7DFD'></code><style id='9C3CCB7DFD'></style>
    • <acronym id='9C3CCB7DFD'></acronym>
      <center id='9C3CCB7DFD'><center id='9C3CCB7DFD'><tfoot id='9C3CCB7DFD'></tfoot></center><abbr id='9C3CCB7DFD'><dir id='9C3CCB7DFD'><tfoot id='9C3CCB7DFD'></tfoot><noframes id='9C3CCB7DFD'>

    • <optgroup id='9C3CCB7DFD'><strike id='9C3CCB7DFD'><sup id='9C3CCB7DFD'></sup></strike><code id='9C3CCB7DFD'></code></optgroup>
        1. <b id='9C3CCB7DFD'><label id='9C3CCB7DFD'><select id='9C3CCB7DFD'><dt id='9C3CCB7DFD'><span id='9C3CCB7DFD'></span></dt></select></label></b><u id='9C3CCB7DFD'></u>
          <i id='9C3CCB7DFD'><strike id='9C3CCB7DFD'><tt id='9C3CCB7DFD'><pre id='9C3CCB7DFD'></pre></tt></strike></i>

          Home / comprehensive / Wikipedia

          Wikipedia


          Wikipedia

          author:leisure time    Page View:5794
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In